Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
A multicenter trial reports that adding middle meningeal artery embolization to surgical evacuation reduced reoperation rates from 11.3% to 4.1% in subdural hematoma patients, though further safety evaluation is needed.
Emergency Medicine December 4th 2024
MDLinx
Phase 2a clinical trials demonstrate benfotiamine’s ability to enhance synaptic activity while maintaining an excellent safety profile, even at doses exceeding normal thiamine blood levels.
Family Medicine/General Practice December 4th 2024
Northwestern Medicine
The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.
Oncology, Medical December 3rd 2024
Oncology News Central (ONC)
Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.
Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.
In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.
Cardiology November 25th 2024